{
  "ticker": "RYTM",
  "company_name": "Rhythm Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05774756",
      "title": "A Trial of Setmelanotide in Acquired Hypothalamic Obesity",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Hypothalamic Obesity",
      "start_date": "2023-04-26",
      "completion_date": "2027-04-16",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06760546",
      "title": "A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome",
      "start_date": "2025-09-23",
      "completion_date": "2027-09-30",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05183802",
      "title": "An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Bardet-Biedl Syndrome (BBS), Obesity",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06596135",
      "title": "Open-Label Extension Study of Setmelanotide",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE3",
      "condition": "Obesity Associated With Defects in Leptin-melanocortin Pathway",
      "start_date": "2024-10-21",
      "completion_date": "2027-10-30",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT01749137",
      "title": "Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Overweight",
      "start_date": "2013-01-14",
      "completion_date": "2013-09-28",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02311673",
      "title": "Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Prader-Willi Syndrome",
      "start_date": "2015-03-19",
      "completion_date": "2016-10-26",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02041195",
      "title": "Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Overweight and Obesity",
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03479437",
      "title": "The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Genetic Forms of Extreme Obesity",
      "start_date": "2018-04-15",
      "completion_date": "2020-12-01",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02849977",
      "title": "Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations",
      "start_date": "2016-09-28",
      "completion_date": "2020-06-09",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06046443",
      "title": "A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Hypothalamic Obesity",
      "start_date": "2024-07-11",
      "completion_date": "2026-01-31",
      "enrollment": 0,
      "sponsor": "Rhythm Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 32,
    "by_phase": {
      "PHASE3": 9,
      "": 7,
      "PHASE2": 9,
      "PHASE1, PHASE2": 2,
      "PHASE1": 3,
      "PHASE2, PHASE3": 1,
      "PHASE4": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 4,
      "RECRUITING": 4,
      "APPROVED_FOR_MARKETING": 1,
      "ENROLLING_BY_INVITATION": 2,
      "COMPLETED": 21
    },
    "active_trials": 10,
    "completed_trials": 21,
    "conditions": [
      "Bardet Biedl Syndrome (BBS), Alstr\u00f6m Syndrome (AS)",
      "Bardet-Biedl Syndrome (BBS), Obesity",
      "Bardet-Biedl Syndrome, POMC Deficiency",
      "Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity",
      "Gene Abnormality, Child Obesity, Hunger",
      "Genetic Forms of Extreme Obesity",
      "Genetic Obesity",
      "Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency",
      "Healthy",
      "Hypertriglyceridemia, Obesity",
      "Hypothalamic Obesity",
      "Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome",
      "Hypothalamic Obesity, Prader-Willi Syndrome, PWS",
      "Leptin Receptor Deficiency Obesity",
      "Obesity",
      "Obesity Associated With Defects in Leptin-melanocortin Pathway",
      "Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly, Polydactyly, Cognitive Impairment, Bardet-Biedl Syndrome, POMC Deficiency",
      "Obesity, Genetic Obesity",
      "Obesity, Morbid Obesity",
      "Overweight",
      "Overweight and Obesity",
      "Overweight, Obese",
      "POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity",
      "Prader-Willi Syndrome",
      "Prader-Willi Syndrome, Obesity, Hyperphagia",
      "Pro-opiomelanocortin (POMC) Deficiency Obesity",
      "Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations",
      "Renal Insufficiency"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:43.642588",
    "search_query": "Rhythm Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Rhythm+Pharmaceuticals,+Inc."
  }
}